RIEMSER Pharma GmbH Ready for the Future 0920 5... · OTC Company Merger of RIEMSER ... 2007 2009 2013 +112%* +484% *First full year with RIEMSER versus last full year with previous

01.05.2011 | Präsentationstitel von Dr. Vorname Nachname 12014 | RIEMSER Pharma GmbH

RIEMSER Pharma GmbH

Ready for the Future

Jefferies Health Care Conference

19th & 20th November 2014

The Waldorf Hilton, London

22014 | RIEMSER Pharma GmbH

Excellence in Marketing and Sales

Strong Market Access and Regulatory experience

Highly efficient BD team

Well-established international partner

network

Fast international market access

Strong marketing capabilities


■ With RIEMSER since April

2011

■ Previously worked for MARS,

BRITA Waterfilters, Teraklin

and Vaillant

Corporate Structure

Kai Deusch, M.D. PhDChief Executive Officer

Beatrice von BuchwaldtChief Financial Officer

■ RIEMSER supervisory board since

Sept. 2012, CEO since Feb. 2014

■ Senior positions in

■ Clinical Academia (Harvard DFCI,

University Munich)

■ Consulting: McKinsey & Company

■ Private Equity: Director, Apax

Partners, Medicis

■ Various pharma & medtech

companies

Advisory BoardElmar Stachels PhD (formerly Bayer)

Thomas Werner PhD (formerly MD GSK,

BMS- Germany)

Burkhart Blank MD (formerly Boehringer I)

Christophe PasikManaging Director Keocyt

(formerly Pfizer France)

EU5-CountryManaging Director

EU5-CountryManaging Director


Phase 1

1991-2008

Phase 2

2009-2012

Phase 3

2012 to date

Strategic Metamorphosis

Divestment of RIEMSER‘s non-

strategic business:

o Dental ORM /OIM

o Manufacturing sites

o Reduction of portfolio by 50% to

approx. 50 products

Geographic (EU) Footprinting

& Strategic Portfolio

Expansion

o Acquisition of Keocyt in

France (04/2014) with 2

Oncology and 2 Neurology

products + pipeline

o Acquisition plans in Italy,

Spain and UK

o Strategic product/portfolio

acquisitions

Consolidation & Strategic Growth

Strategic focus on oncology, anti-

infectives and dermatology

Targeted acquisitions and

developments (Aloxi, Ostac,Tepadina)

and divestments (animal health)

Initiation of internationalization

Diversified Pharma / Device /

OTC Company

Merger of RIEMSER

Tierarzneimittel (animal health)

with Palmicol into RIEMSER

Arzneimittel GmbH

Acquisition of dental business

and 400+ marketing

authorisations

Dynamic Development Acquisition by

Ardian Private Equity


Continuous Growth

Sales close to € 110m in 2014CAGR (%)

9.2%

13.9%

6.7%

68%

71% 68% 61% 62%

32%

29%

32%

39% 38%

2009 2010 2011 2012 2013

National International


Re-launch and repositioning of

existing products

Launch of innovative niche products

and orphan drugs

Acquisition and integration

capabilities

Licensing of strategic products

Core Competencies

Anti-infectives 22%

Dermatology 8%

Oncology 30%

Cardiovascular15%

Others 25%(e.g. Immunology/

Obesity)

Global distribution network


Key Therapeutic Areas

Tepadina

Aloxi

Ostac

Gelclair

Zanosar

Estracyt

Akynzeo*

Dedicated sales

force in Germany

and France

Dilantin

Prodilantin

Dedicated sales

force in France

Vancomycin

Enterocaps

Eremfat

KOL network

Direct Marketing

Cardiovascular

Vagantin

Bite-away

Herpotherm

KOL network

Direct Marketing

Lanitop

Ismo

Aldactone

KOL network

Direct Marketing

*pre-approval phase

DermatologyAnti-InfectivesNeurologyOncology


RIEMSER Can Make a Difference (1)

Aloxi

5-HT3 receptor antagonist

for prevention of CT-

induced nausea and

vomiting

Launched in 2005

In-licensed from Helsinn in

2008 after flattened sales

development by previous

licensee

Re-positioning as “best-in-

class” setron

0

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

8,000,000

2007 2009 2013

+112%*

+484%

*First full year with RIEMSER versus last full year with previous licensee

Retail Sales (€)



Tepadina

For conditioning treatment

prior to HSCT

Developed in a global

partnership with Adienne

New MA granted in 3/2010

New positioning with

orphan drug status at an

attractive price

Expansion into new

indications and markets

(France, selected Eastern

European countries, Asia)

*First year after repositioning versus previous year

0

1,000,000

2,000,000

3,000,000

4,000,000

5,000,000

6,000,000

7,000,000

8,000,000

9,000,000

10,000,000

2009 2010 2013

+171%*

+557%Sales (€)



Bite-away

Electrical device to treat

insect bites

Initiation of direct-to-customer

promotion in 2013

Usage by celebrities

Distribution through Amazon

etc.

Line extension for the

treatment of herpes labialis

*First year after start of DTC promotion versus previous year

0

200,000

400,000

600,000

800,000

1,000,000

1,200,000

1,400,000

1,600,000

1,800,000

2012 2013

+170%*

Sales (€)


Mission & Strategy

Mission

Establish a leading European

specialty pharma player

o Marketing & distribution

excellence in complex disease

areas

o Efficient BD transaction team

o Proprietary deal flow through

unique network

o Ideal partner for innovative

companies to launch specialty

products in Europe

Strategy

Focus on therapeutics and supportive

care products around selected

complex disease areas

Employ/grow expert market access &

distribution know how

Establish solid footprint in key

European regions through targeted

acquisitions


Becoming an European Specialty Pharma Player

Riemser France

Riemser Europe

Transition towards a fully integrated European company


Worldwide Distribution Network with Trusted Partners

SP = specialty pharma products, EP= established pharma products


Key Priorities for the Future

Focus on Key

Therapeutic Areas

Continue Acquisition

and Licensing Strategy

Expand European

Footprint

• Build on existing expertise in Oncology,

Dermatology, Anti-infectives and

Cardiovascular

• Use existing competencies to tap into

Autoimmune diseases, Immunology,

Neurology and Transplantation

• Experienced and flexible team

• Efficient and effective execution

• Establish affiliates in all Big 5 countries

• Become an European specialty pharma player

with an entrepreneurial spirit

• Manage and expand current well- functioning

partner network


RIEMSER is your preferred partner for:

Company Acquisitions

Product Acquisition

LicensingCo-

promotion

Co-detailing


Highly focused specialty pharma company ideally suited to serve as partner for innovative

pharma companies targeting disease areas with high unmet medical need

Rich global pipelines in oncology, immunology and other complex/niche chronic diseases

require highly specialized partners such as RIEMSER

Rise of personalized medicine requires more refined sales strategies than in the past

RIEMSER is perfectly positioned to market innovative, non-mainstream

therapeutics in oncology, autoimmunity, neurology and other specialty niches

RIEMSER Pharma

In Summary


THANK YOU

Documents

RIEMSER Pharma GmbH Ready for the Future 0920 5... · OTC Company Merger of RIEMSER ... 2007 2009 2013 +112%* +484% *First full year with RIEMSER versus last full year with previous